PharmaSGP Holding SE
XETRA:PSG
PharmaSGP Holding SE
XETRA:PSG
Price:
24.6
EUR
-0.81%
Market Closed
Market Cap:
295.2m
EUR
PharmaSGP Holding SE
Revenue
|
PharmaSGP Holding SE
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Revenue
€101.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Revenue
$314k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Revenue
€46.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Merck KGaA
XETRA:MRK
|
Revenue
€21B
|
CAGR 3-Years
3%
|
CAGR 5-Years
6%
|
CAGR 10-Years
7%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Revenue
€25.8k
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Revenue
€1.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
PharmaSGP Holding SE
Glance View
PharmaSGP Holding SE engages in the sale and marketing of non-prescription drugs, chemical-free over-the-counter painkillers, as well as herbal medicines. The company is headquartered in Graefelfing, Bayern. The company went IPO on 2020-06-19. The firm produces and develops non-chemical and over-the-counter drugs and other healthcare products.
PSG
Intrinsic Value
41.65
EUR
Undervaluation 41%
See Also
What is PharmaSGP Holding SE's Revenue?
Revenue
101.1m
EUR
101.1m
EUR
Based on the financial report for Dec 31, 2023, PharmaSGP Holding SE's Revenue amounts to 101.1m EUR.
What is PharmaSGP Holding SE's Revenue growth rate?
Revenue CAGR 5Y
11%
11%
Over the last year, the Revenue growth was 18%. The average annual Revenue growth rates for PharmaSGP Holding SE have been 17% over the past three years , 11% over the past five years .
You don't have any saved screeners yet